India's Dengue Vaccine 'DengiAll' Nears Approval After 17 Years of Research
News
F
Firstpost•07-01-2026, 17:42
India's Dengue Vaccine 'DengiAll' Nears Approval After 17 Years of Research
- •India's indigenous dengue vaccine, DengiAll, developed by Panacea Biotec with ICMR support, is in its final Phase-III trials.
- •The vaccine, under development for over 15 years, aims to protect against all four dengue virus serotypes in a single shot.
- •Phase-III trials, which began in August 2024, involved over 10,000 volunteers across nearly 20 sites in India.
- •Earlier trials showed 77-82% protection; regulatory approval is now the crucial next step.
- •If approved, DengiAll could significantly impact dengue prevention in India and other tropical regions globally.
Why It Matters: After 17 years, India's DengiAll vaccine is poised to revolutionize global dengue prevention.
✦
More like this
Loading more articles...
